Lead Product(s) : Tolvaptan
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Receives USFDA Approval for Tolvaptan Tablets
Details : Jynarque-Generic (tolvaptan) is a selective vasopressin V2-receptor antagonist indicated to slow kidney function decline in adults at risk of autosomal dominant polycystic kidney disease.
Product Name : Jynarque-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 24, 2025
Lead Product(s) : Tolvaptan
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolvaptan
Therapeutic Area : Nephrology
Study Phase : Approved FDF
Sponsor : Millmount Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oral vasopressin V2-receptor antagonists Samsca® Tablets, Samsca® OD Tablets and SAMSCA® Granules 1% have received regulatory approval in Japan for the indication of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secreti...
Product Name : Samsca
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 29, 2020
Lead Product(s) : Tolvaptan
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Sponsor : Millmount Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
